Mary Rusckowski to Colonic Neoplasms
This is a "connection" page, showing publications Mary Rusckowski has written about Colonic Neoplasms.
Connection Strength
0.700
-
Xiao N, Cheng D, Wang Y, Chen L, Liu X, Dou S, Liu G, Liang M, Hnatowich DJ, Rusckowski M. Identification of a high affinity TAG-72 binding peptide by phage display selection. Cancer Biol Ther. 2011 Jan 01; 11(1):22-31.
Score: 0.078
-
Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
Score: 0.077
-
Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer. 2009 Nov; 45(17):3098-103.
Score: 0.072
-
Chen L, Wang Y, Liu X, Dou S, Liu G, Hnatowich DJ, Rusckowski M. A new TAG-72 cancer marker peptide identified by phage display. Cancer Lett. 2008 Dec 08; 272(1):122-32.
Score: 0.067
-
Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging. 2007 Feb; 34(2):237-46.
Score: 0.060
-
Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging. 2005 Sep; 32(9):1115-23.
Score: 0.054
-
He J, Liu G, Gupta S, Zhang Y, Rusckowski M, Hnatowich DJ. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med. 2004 Jun; 45(6):1087-95.
Score: 0.050
-
Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, Hnatowich DJ. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004 Mar; 31(3):417-24.
Score: 0.048
-
Ferro-Flores G, Arteaga de Murphy C, Pedraza-L?pez M, Mel?ndez-Alafort L, Zhang YM, Rusckowski M, Hnatowich DJ. In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl Med Biol. 2003 Aug; 30(6):597-603.
Score: 0.047
-
Liu G, Liu C, Zhang S, He J, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Investigations of 99mTc morpholino pretargeting in mice. Nucl Med Commun. 2003 Jun; 24(6):697-705.
Score: 0.046
-
Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med. 2002 Mar; 43(3):384-91.
Score: 0.042
-
Rescigno A, Bushe H, Brill AB, Rusckowski M, Griffin TW, Hnatowich DJ. Pharmacokinetic modeling of radiolabeled antibody distribution in man. Am J Physiol Imaging. 1990; 5(4):141-50.
Score: 0.018
-
Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
Score: 0.016
-
Rusckowski M, Doherty PW, Virzi F, Hnatowich DJ. A simple in vitro method of screening panels of monoclonal antibodies for tumor binding. J Immunol Methods. 1985 Feb 11; 76(2):375-82.
Score: 0.013
-
Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem. 2002 May-Jun; 13(3):561-70.
Score: 0.011